nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.05.2011 | Original Paper

Clinical significance of EphA2 expression in squamous-cell carcinoma of the head and neck

verfasst von: Yong Liu, Xin Zhang, Yuanzheng Qiu, Donghai Huang, Shuai Zhang, Li Xie, Lin Qi, Changyun Yu, Xiaojuan Zhou, Guoqing Hu, Yongquan Tian

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

EphA2 receptor tyrosine kinase is frequently overexpressed and functionally altered in a variety of human cancers. The study aimed to assess EphA2 expression and to explore its roles in squamous-cell carcinoma of the head and neck (SCCHN).

Methods

EphA2 expression in 98 primary SCCHN tissue specimens was analyzed by immunohistochemistry and correlated with clinicopathological parameters. Additionally, 13 paired SCCHN tissues and 6 SCCHN cell lines were evaluated for EphA2 expression by RT–PCR and immunoblotting.

Results

EphA2 overexpressed in SCCHN tissues and SCCHN cell lines. More importantly, high EphA2 expression was significantly associated with tumor site, T classification, clinical stage, recurrence, and lymph node metastasis, respectively. Patients with high EphA2 expression had both poorer disease-free survival and overall survival than patients with low EphA2 expression. Multivariate Cox regression analysis revealed that EphA2 overexpression was an independent prognostic factor for patients with SCCHN.

Conclusions

These findings suggested that EphA2 may contribute to SCCHN progression and represent a novel prognostic indicator for patients with SCCHN.

Abraham S, Knapp DW, Cheng L et al (2006) Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 12:353–360PubMedCrossRef

Brannan JM, Dong W, Prudkin L et al (2009) Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res 15:4423–4430PubMedCrossRef

Brantley-Sieders DM, Caughron J, Hicks D et al (2004) EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J Cell Sci 117:2037–2049PubMedCrossRef

Brantley-Sieders DM, Fang WB, Hwang Y et al (2006) Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res 66:10315–10324PubMedCrossRef

Brantley-Sieders DM, Zhuang G, Hicks D et al (2008) The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 118:64–78PubMedCrossRef

Dodelet VC, Pasquale EB (2000) Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 19:5614–5619PubMedCrossRef

Duxbury MS, Ito H, Zinner MJ et al (2004) RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 23:1539–1548PubMedCrossRef

Herath NI, Spanevello MD, Sabesan S et al (2006) Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival. BMC Cancer 6:144PubMedCrossRef

Herrem CJ, Tatsumi T, Olson KS et al (2005) Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res 11:226–231PubMed

Hess AR, Seftor EA, Gardner LM et al (2001) Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 61:3250–3255PubMed

Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96PubMedCrossRef

Kamat AA, Coffey D, Merritt WM et al (2009) EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer 115:2684–2692PubMedCrossRef

Kikawa KD, Vidale DR, Van Etten RL et al (2002) Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J Biol Chem 277:39274–39279PubMedCrossRef

Kinch MS, Moore MB, Harpole DH Jr (2003) Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 9:613–618PubMed

Kullander K, Klein R (2002) Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 3:475–486PubMedCrossRef

Liu F, Park PJ, Lai W et al (2006) A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. Cancer Res 66:10815–10823PubMedCrossRef

Lu C, Shahzad MM, Wang H et al (2008) EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther 7:1098–1103PubMedCrossRef

Ma LJ, Li W, Zhang X et al (2009) Differential gene expression profiling of laryngeal squamous cell carcinoma by laser capture microdissection and complementary DNA microarrays. Arch Med Res 40:114–123PubMedCrossRef

Macrae M, Neve RM, Rodriguez-Viciana P et al (2005) A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 8:111–118PubMedCrossRef

Miyazaki T, Kato H, Fukuchi M et al (2003) EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 103:657–663PubMedCrossRef

Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef

Parri M, Taddei ML, Bianchini F et al (2009) EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style. Cancer Res 69:2072–2081PubMedCrossRef

Pasquale EB (2005) Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 6:462–475PubMedCrossRef

Pasquale EB (2008) Eph-ephrin bidirectional signaling in physiology and disease. Cell 133:38–52PubMedCrossRef

Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705–1715PubMedCrossRef

Rivera RS, Gunduz M, Nagatsuka H et al (2008) Involvement of EphA2 in head and neck squamous cell carcinoma: mRNA expression, loss of heterozygosity and immunohistochemical studies. Oncol Rep 19:1079–1084PubMed

Saito T, Masuda N, Miyazaki T et al (2004) Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. Oncol Rep 11:605–611PubMed

Sobin LH, Wittekind CH (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, New York

Straume O, Akslen LA (2002) Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. Am J Pathol 160:1009–1019PubMedCrossRef

Sulman EP, Tang XX, Allen C et al (1997) Eck, a human eph-related gene, maps to 1p36.1, a common region of alteration in human cancers. Genomics 40:371–374PubMedCrossRef

Taddei ML, Parri M, Angelucci A et al (2009) Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis. Am J Pathol 174:1492–1503PubMedCrossRef

Thaker PH, Deavers M, Celestino J et al (2004) EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 10:5145–5150PubMedCrossRef

Walker-Daniels J, Riese DJ 2nd, Kinch MS (2002) c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol Cancer Res 1:79–87PubMed

Wu D, Suo Z, Kristensen GB et al (2004) Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma. Gynecol Oncol 94:312–319PubMedCrossRef

Yang NY, Pasquale EB, Owen LB et al (2006) The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization. J Biol Chem 281:32574–32586PubMedCrossRef

Yuan WJ, Ge J, Chen ZK et al (2009) Over-expression of EphA2 and EphrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients. Dig Dis Sci 54:2410–2417PubMedCrossRef

Zantek ND, Azimi M, Fedor-Chaiken M et al (1999) E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ 10:629–638PubMed

Zelinski DP, Zantek ND, Stewart JC et al (2001) EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61:2301–2306PubMed

Zhang X, Liu Y, Gilcrease MZ et al (2002) A lymph node metastatic mouse model reveals alterations of metastasis-related gene expression in metastatic human oral carcinoma sublines selected from a poorly metastatic parental cell line. Cancer 95:1663–1672PubMedCrossRef

Titel: Clinical significance of EphA2 expression in squamous-cell carcinoma of the head and neck
verfasst von: Yong Liu
Xin Zhang
Yuanzheng Qiu
Donghai Huang
Shuai Zhang
Li Xie
Lin Qi
Changyun Yu
Xiaojuan Zhou
Guoqing Hu
Yongquan Tian
Publikationsdatum: 01.05.2011
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 5/2011
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-010-0936-2

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Clinical significance of EphA2 expression in squamous-cell carcinoma of the head and neck